HomeCompareESKYF vs ABBV

ESKYF vs ABBV: Dividend Comparison 2026

ESKYF yields 689.66% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ESKYF wins by $803540.37M in total portfolio value
10 years
ESKYF
ESKYF
● Live price
689.66%
Share price
$0.29
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$803540.47M
Annual income
$625,208,037,467.50
Full ESKYF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ESKYF vs ABBV

📍 ESKYF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodESKYFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ESKYF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ESKYF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ESKYF
Annual income on $10K today (after 15% tax)
$58,620.69/yr
After 10yr DRIP, annual income (after tax)
$531,426,831,847.38/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ESKYF beats the other by $531,426,810,791.37/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ESKYF + ABBV for your $10,000?

ESKYF: 50%ABBV: 50%
100% ABBV50/50100% ESKYF
Portfolio after 10yr
$401770.29M
Annual income
$312,604,031,119.63/yr
Blended yield
77.81%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ESKYF
No analyst data
Altman Z
19.4
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ESKYF buys
0
ABBV buys
0
No recent congressional trades found for ESKYF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricESKYFABBV
Forward yield689.66%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$803540.47M$102.3K
Annual income after 10y$625,208,037,467.50$24,771.77
Total dividends collected$789060.81M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ESKYF vs ABBV ($10,000, DRIP)

YearESKYF PortfolioESKYF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$79,666$68,965.52$11,550$430.00+$68.1KESKYF
2$598,716$513,474.17$13,472$627.96+$585.2KESKYF
3$4,247,123$3,606,496.41$15,906$926.08+$4.23MESKYF
4$28,454,196$23,909,774.76$19,071$1,382.55+$28.44MESKYF
5$180,153,369$149,707,379.48$23,302$2,095.81+$180.13MESKYF
6$1,078,604,537$885,840,431.45$29,150$3,237.93+$1078.58MESKYF
7$6,110,794,755$4,956,687,900.70$37,536$5,121.41+$6110.76MESKYF
8$32,783,349,397$26,244,799,009.40$50,079$8,338.38+$32783.30MESKYF
9$166,665,824,043$131,587,640,188.37$69,753$14,065.80+$166665.75MESKYF
10$803,540,469,194$625,208,037,467.50$102,337$24,771.77+$803540.37MESKYF

ESKYF vs ABBV: Complete Analysis 2026

ESKYFStock

Eskay Mining Corp., a natural resource company, engages in the acquisition and exploration of mineral properties, and precious and base metal deposits in British Columbia, Canada. It holds 100% interests in the St. Andrew Goldfield project located at Eskay Creek; Volcanogenic Massive Sulphide project situated in the Golden Triangle; and Corey mineral claims located in the Skeena Mining division. The company was formerly known as Kenrich-Eskay Mining Corp. and changed its name to Eskay Mining Corp. in November 2009. Eskay Mining Corp. was founded in 1980 and is headquartered in Toronto, Canada.

Full ESKYF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ESKYF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ESKYF vs SCHDESKYF vs JEPIESKYF vs OESKYF vs KOESKYF vs MAINESKYF vs JNJESKYF vs MRKESKYF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.